SGLT-2 inhibitors can reduce inflammatory markers such as interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor (TNF-α), thereby alleviating arteriosclerosis in diabetes animal models [15]. This evidence concerns the gene CCL2 and diabetes mellitus.